Sanofi Announces Strategic Shift: Exits Diabetes and Cardiovascular R&D to Focus on Specialty and Rare Diseases

News Event

Today, Paul Hudson, the new CEO of pharmaceutical giant Sanofi, announced his strategic agenda. The primary strategic shift involves exiting research and development in diabetes and cardiovascular diseases, thereby saving approximately €2.2 billion in R&D expenditures. Already marketed products will be integrated into the General Medicines division and managed as mature products. Sanofi’s growth will be driven by the development of drugs for rare and specialized diseases, with a key objective of establishing Dupixent, an IL-4α receptor antibody, as a blockbuster product generating billions of dollars in revenue. Hudson stated that henceforth, all launched products must be disruptive, eliminating “me-too” and “me-too-late” projects.

Drug Source Analysis

Sanofi, a giant in the fields of cardiovascular disease and diabetes, once created the blockbuster drugs Plavix and the heavyweight insulin Lantus. Its withdrawal from these two high-prevalence common diseases truly signals that the pharmaceutical landscape is no longer what it used to be. Coincidentally, last month, Sanofi’s long-time rival Amgen also announced its exit from R&D in another area of common diseases—central nervous system disorders—and subsequently signed a $2.7 billion collaboration agreement with BeiGene to jointly develop oncology drugs. Three main factors are forcing these traditional large pharmaceutical companies to step out of their comfort zones and abandon the R&D, marketing, and regulatory approval support systems they have meticulously built over many years: first, the dominance of standard therapies; second, the excessive complexity of technology; and third, changes in the reimbursement environment.

The modern pharmaceutical industry originated in anti-infectives but matured with the extensive discovery of drugs for common diseases prevalent in the general population. Although these medications have made the pharmaceutical industry one of the most profitable sectors and a major contributor to GDP, they have also rendered sustainable development an increasingly challenging task. While diabetes and cardiovascular diseases represent large markets, there are already dozens of highly effective drugs across more than ten therapeutic classes for each condition. Many drugs that once significantly improved human health now cost less than placebos due to patent expirations, making it far more difficult for new drugs to outperform these established agents in clinical trials than to simply beat a placebo. Even if a new drug possesses unique efficacy, demonstrating sufficient differentiation from these well-established competitors typically requires clinical trials involving tens of thousands of participants and hundreds of millions of dollars in R&D investment. In contrast, gene therapies can achieve valuations nearing billions of dollars with clinical data from only a dozen or so patients. For chronic disease medications, achieving either a substantial improvement in hard clinical endpoints or a significant enhancement in convenience (such as inclisiran, a PCSK9 RNAi therapeutic administered via injection every six months) is nearly impossible.

It is unlikely that the complexity of disease pathology alone accounts for this challenge. Although these conditions all involve hyperglycemia, their underlying molecular mechanisms vary considerably, as do their complications. While two classes of glucose-lowering agents—GLP-1 receptor agonists and SGLT2 inhibitors—have been shown to improve cardiovascular outcomes, their benefits are largely independent of glycemic control. Consequently, replicating such successes is exceedingly difficult, and surpassing them remains an elusive goal. Established medications can safely lower blood glucose, lipids, and blood pressure; therefore, any new drug that fails to demonstrate improvement in hard clinical endpoints must substantially enhance patient adherence to be viable. The potency of conventional small-molecule drugs is typically insufficient to sustain therapeutic effects with dosing intervals of six months or one year; only nucleic acid-based therapies currently achieve such durability. Even highly potent agents like GLP-1 receptor agonists still require weekly administration. However, common prevalent diseases exhibit high heterogeneity, making adverse reactions difficult to predict. Thus, for a once-yearly injection, strategies to reverse potential adverse events must be carefully considered. Inclisiran represents a unique case: among common prevalent diseases, it is difficult to identify another target besides PCSK9 that enables such precise modulation of a robust biomarker (LDL cholesterol) with such a favorable safety profile.

PCSK9 inhibitors may well be Sanofi’s sore spot, much as they are for Amgen. Drugs for common diseases not only struggle to demonstrate meaningful differentiation but also face stricter scrutiny from payers. Given the potential for massive utilization if access were loosened, many had feared that PCSK9 inhibitors would bankrupt payers; unexpectedly, it was the manufacturers themselves who nearly faced bankruptcy. Currently, oncology drugs and orphan drugs enjoy broad payer acceptance with minimal controversy. However, as industry giants like Amgen and Sanofi pivot their strategies, a large influx of such therapies is expected to enter the market. Since payer capacity will not increase significantly, shifting focus toward specialty disease medications is merely a stopgap measure. In fact, payer capacity may decline substantially, as both major U.S. political parties have recently proposed strategies to lower drug prices. The root cause underlying these policies is society’s undervaluation of the benefits of new medicines, with drugs for prevalent, mass-market conditions being most vulnerable to this undervaluation. While no one can precisely quantify—nor perhaps should prioritize—the monetary value of a single human life, what matters is that if society is willing to spend X thousand dollars to save a life, individuals will invest Y hundred million dollars to discover life-saving treatments. With hundreds of millions of diabetes patients worldwide and cardiovascular disease remaining the leading cause of death in most countries, the widespread withdrawal of major pharmaceutical companies from these therapeutic areas is hardly a positive development. As Mary Lasker famously stated, “If you think medicines are expensive, try disease.”

Original Title: Exclusive | Sanofi Exits Diabetes